The aim of this study is to investigate epigenetic mechanism of ABCG2 induced drug-resistance. It is not only expatiate for drug-resistance regulation mechanism in all-round, but also to provide scientific experimental basis for selecting target to reverse its drug-resistance. Apply methylation-specific PCR （MSP） to have tested methylation of ABCG2 promoter region -359 to -353 specific positions in breast cancer tissues and paired adjacent tissue of 22 cases and test their methylation positions with MSP products for sequencing; and adopt fluorescent quantitation RT-PCR to test expression level DNMT1, DNMT3A, DNMT3B and ABCG2; to make analysis on relationship between them with statistical spearman correlation. Specific positions of ABCG2 gene promoter region of 18 cases among the 22 cases with breast cancer （18/22, 82%） existed high methylation （P〈0.05）, MSP products sequencing proved methylation of the specific position, and mRNA expression level was relative higher in remarkable positive correlation （P〈0.05） ABCG2, DNMT1, DNMT3A, DNMT3B mRNA expression levels in breast cancer tissues were obviously higher than adjacent tissues （P〈0.01）, and DNMT3B expression level was obviously higher than DNMT1 and DNMT3A （P〈0.01） in negative correlation with ABCG2 gene expression （P=0.001）. -359 to -353 positions of promoter regions of ABCG2gene existed high methylation capable to push expression of this gene in beast cancer tissue. DNMT3B is involved in expression regulation in ABCG2 gene, and provides new scientific basis for drug-resistance target as reverse ABCG2 induction
Yuan Jianhui Zhou Jianmeng JiNana Xu Xinyun Liu Jianjun Ke Yuebin Cheng Jinquan． Zhuang Zhixiong
目的研究乳腺癌细胞(MCF-7)经米托蒽醌诱导耐药后其甲基化结合蛋白(Methyl-DNA-binding protein,MBD)的表达变化,并分析在MCF-7细胞经诱导产生多药耐药性中与甲基化结合蛋白的关系。方法利用耐米托蒽醌的MCF-7耐药株,并用未染毒的野生型MCF-7为对照,通过蛋白印迹法检测不同浓度米托蒽醌处理的细胞组乳腺癌耐药蛋白(breast cancer resistance protein,BCRP)和甲基化结合蛋白MBD1、MBD2及MBD4的蛋白表达水平。结果跟野生型MCF-7比较,随着染毒浓度的增大,乳腺癌耐药蛋白BCRP的表达逐渐增加,而MBD1、MBD2、MBD4的表达均呈降低趋势,且MBD4的降低尤为明显,与对照组比较,其MBD4蛋白表达水平分别为(0.910±0.049)、(0.835±0.065)、(0.708±0.082)、(0.660±0.145)(P<0.05)。结论在米托蒽醌诱导产生耐药的MCF-7细胞株中,MBDs的表达,尤其是MBD4,有可能参与了肿瘤耐药的形成。
